Abstract：
BACKGROUND: Major depressive disorder is related to unfavourable outcomes in patients with severe comorbidities. In transplant patients, major depression is associated with worse clinical outcomes.
METHODS: We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a score of 20/27 on the PHQ-9 depression screening scale. After receiving mirtazapine 30 mg/night for a week and persisting with a high suicide risk, it was decided to administer ketamine infusion for 24 h, with which a significant improvement in mood was observed, and the disappearance of suicidal ideation 24 h after the infusion.
CONCLUSIONS: Depression in transplant patients is a factor associated with graft loss and post-transplant mortality, in addition to favouring other negative outcomes such as deep vein thrombosis.
CONCLUSIONS: Ketamine infusion was shown to be an effective and safe option to treat major depression with suicidal risk in a heart transplant patient.
METHODS: We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a score of 20/27 on the PHQ-9 depression screening scale. After receiving mirtazapine 30 mg/night for a week and persisting with a high suicide risk, it was decided to administer ketamine infusion for 24 h, with which a significant improvement in mood was observed, and the disappearance of suicidal ideation 24 h after the infusion.
CONCLUSIONS: Depression in transplant patients is a factor associated with graft loss and post-transplant mortality, in addition to favouring other negative outcomes such as deep vein thrombosis.
CONCLUSIONS: Ketamine infusion was shown to be an effective and safe option to treat major depression with suicidal risk in a heart transplant patient.
摘要：
背景：重度抑郁症与严重合并症患者的不良结局有关。在移植患者中，重度抑郁症与较差的临床结局相关。
方法：我们介绍了一例55岁男性因缺血性心力衰竭进行心脏移植的病例。移植六个月后，他情绪抑郁，在PHQ-9抑郁筛查量表上，快感和自杀意念评分为20/27。在接受米氮平30毫克/晚持续一周并持续存在高自杀风险后，决定输注氯胺酮24小时，观察到情绪显着改善，输注后24小时自杀意念消失。
结论：移植患者的抑郁是与移植物丢失和移植后死亡率相关的一个因素。除了有利于其他负面结果，如深静脉血栓形成。
结论：氯胺酮输注被证明是治疗心脏移植患者有自杀风险的重度抑郁症的有效和安全的选择。
方法：我们介绍了一例55岁男性因缺血性心力衰竭进行心脏移植的病例。移植六个月后，他情绪抑郁，在PHQ-9抑郁筛查量表上，快感和自杀意念评分为20/27。在接受米氮平30毫克/晚持续一周并持续存在高自杀风险后，决定输注氯胺酮24小时，观察到情绪显着改善，输注后24小时自杀意念消失。
结论：移植患者的抑郁是与移植物丢失和移植后死亡率相关的一个因素。除了有利于其他负面结果，如深静脉血栓形成。
结论：氯胺酮输注被证明是治疗心脏移植患者有自杀风险的重度抑郁症的有效和安全的选择。
